An efficient, microwave/ultrasound-irradiated
synthesis of novel
chromenopyrimidines has been established. 2-Amino-5-oxo-4-(thiophen-2-yl)-5,6,7,8-tetrahydro-4
H
-chromene-3-carbonitrile (
1
) underwent cyclization
reactions with various assorted reagents under sustainable conditions
to afford a family of fused pyrimidine derivatives. The proposed structures
of the designed fused pyrimidines were confirmed by several spectral
techniques. Moreover, the targeted pyrimidines were estimated for
their in vitro cytotoxic activities toward three carcinoma cell lines:
breast (MCF7), hepatocyte (HepG2), and lung (A549) cancer cell lines,
as well as one noncancerous cell line (MCF-10A). Structure–activity
relationship (SAR) analyses revealed that derivatives
3
and
7
exhibited the highest potency in inhibiting the
growth of cancer cells tested in vitro. Particularly, 3-amino-4-imino-5-(thiophen-2-yl)-3,4,5,7,8,9-hexahydro-6
H
-chromeno[2,3-
d
]pyrimidin-6-one (
3
) displayed a robust impact with IC
50
values ranging
from 2.02 to 1.61 μM. Interestingly, compound
3
was observed to have low cytotoxicity toward noncancerous cell (MCF-10A)
compared to the standard drug (Doxorubicin). Further, quantum chemical
computations of the designed molecules utilizing density functional
theory (DFT) were conducted and shown to be compatible with the observed
antiproliferative properties. Thorough docking investigations revealed
that the assembled compounds possess exceptionally low binding energies
toward our three selected proteins:
4b3z
-Lung, HepG2–
2JW2
, and
6ENV
-MCV-7. Based on
these intriguing results, compound
3
could be further
evaluated for preclinical screening, potentially paving the way for
its utilization as a promising cancer treatment.